UK Biologics Safety Testing Market (2026-2031)
The UK Biologics Safety Testing Market was valued at $339.6 Million in 2026 and projected to reach to $584.9 Million by 2031, representing a compound annual growth rate of 11.5%. The UK biologics safety testing market is poised for sustained expansion, growing from $339.6 million in 2026 to $584.9 million by 2031, representing an 11.5% CAGR.
UK Biologics Safety Testing Market Trends and Insights
- The UK market is driven by stringent regulatory requirements from the MHRA and EMA, increasing biopharmaceutical development, and rising demand for advanced safety assessment methodologies.
- The UK's position as a leading life sciences hub in Europe supports continued investment in testing infrastructure and innovation. The UK market benefits from a strong pharmaceutical and biotechnology sector, with numerous contract research organizations (CROs) and testing facilities operating across the country.
- Between 2026 and 2031, the UK is expected to see accelerated adoption of in vitro and alternative testing methods, driven by regulatory modernization and industry pressure to reduce animal testing.
- The UK's commitment to maintaining high safety standards while supporting innovation positions it as a critical market within the European biologics safety testing landscape..
Key Market Statistics
- CAGR (2026-2031) 11.5% CAGR
- Market Size, 2026 ~USD 339.6 Million
- Forecast, 2031 ~USD 584.9 Million
- Country UK
UK Biologics Safety Testing Market Overview
MHRA & EMA Regulatory Compliance :
The UK's stringent regulatory framework from the Medicines and Healthcare products Regulatory Agency (MHRA) and alignment with European Medicines Agency (EMA) standards drive demand for comprehensive biologics safety testing solutions across pharmaceutical companies.
Leading Life Sciences Hub Status :
The UK's position as a premier life sciences cluster, with major biotech hubs in Cambridge, Oxford, and London, accelerates biopharmaceutical development and increases investment in advanced safety assessment methodologies and testing infrastructure.
Rapid Biopharmaceutical Pipeline Growth :
UK-based biopharmaceutical companies are expanding their development pipelines, necessitating robust safety testing protocols. This growth is supported by government initiatives and venture capital funding in the life sciences sector.
Advanced Testing Methodology Adoption :
UK laboratories are increasingly adopting in vitro, in silico, and alternative testing methods to replace traditional animal testing, driven by regulatory preferences and ethical considerations under UK and EU frameworks.
UK Biologics Safety Testing Market Dynamics
- This growth trajectory is underpinned by the UK's commitment to maintaining world-class regulatory standards post-Brexit and the continued strength of its biopharmaceutical sector.
- Increased R&D spending by UK biotech firms and contract research organizations (CROs) will drive demand for specialized safety testing services. Key growth drivers include the rising complexity of biologic molecules, heightened focus on patient safety, and regulatory pressure for comprehensive preclinical and clinical safety data.
- The UK market will benefit from technological innovations in testing platforms, growing outsourcing trends among smaller biotech companies, and government support for life sciences infrastructure development.
- Strategic investments in testing capabilities and talent acquisition will remain critical for market participants..
Related Ecosystem
Biotechnology
- Reagents
- Polymerase Chain Reaction (PCR)
- Stem Cells
- Assay Kits
- Flow Cytometers
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Danaher Corporation
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
Key Takeaways
- The UK biologics safety testing market will grow from $339.6M (2026) to $584.9M (2031), representing a 11.5% CAGR.
- The UK's regulatory framework and MHRA oversight drive demand for comprehensive safety testing across all biopharmaceutical development stages.
- The UK market is shifting toward alternative testing methods and in vitro technologies to meet evolving regulatory and ethical standards.
- The UK's established CRO sector and life sciences infrastructure position it as a key hub for biologics safety testing in Europe.
Biologics Safety Testing Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | STERILITY TESTING SERVICES (Application) |
| Forecast Period | 2026–2031 |
| Growth Rate | CAGR of 11.6% from 2026 to 2031 |
| Largest Segment | SERVICES (Offering) |
| Market Size Base Year (Billions) | ~USD 5.58 (2026) |
| Revenue Forecast (Billions) | ~USD 9.66 (2031) |
| Segments Covered | Offering, Type, Product & Service, Test Type, Application, End User |
UK Biologics Safety Testing Market Report Segmentation
6 segment dimensions are covered across the global market.
By Offering
- Products
- Services
By Type
- Bioburden Testing Services
- Endotoxin Testing Services
- Mycoplasma Testing Services
- Other Biologics Safety Testing Services
- Other Bst Services
- Sterility Testing Services
- Virus Safety Testing Services
By Product & Service
- Consumables
- Instruments
- Services
By Test Type
- Bioburden Tests
- Endotoxin Tests
- Mycoplasma Tests
- Other Biologics Safety Tests
- Residual Host Cell Proteins & Dna Detection Tests
- Sterility Tests
- Virus Safety Tests
By Application
- Blood & Blood Products Development And Manufacturing
- Cellular & Gene Therapy Products Development And Manufacturing
- Monoclonal Antibodies Development And Manufacturing
- Other Applications
- Vaccines Development And Manufacturing
By End User
- Academic & Research Institutes
- Cros & Cdmos
- Pharmaceutical & Biotechnology Companies
Target Audience
- Biopharmaceutical Companies : UK-based and international pharma firms operating in the UK need comprehensive market data to optimize their safety testing budgets, select appropriate CRO partners, and ensure regulatory compliance with MHRA standards.
- Contract Research Organizations (CROs) : UK and European CROs require detailed market intelligence to benchmark their service offerings, identify growth opportunities, and understand competitive positioning within the rapidly expanding UK biologics testing market.
- Testing Laboratory Operators : Independent and hospital-based testing laboratories need market insights to plan capacity expansion, invest in new testing technologies, and develop service portfolios aligned with UK regulatory and customer demands.
- Life Sciences Investors & Venture Capitalists : Investment firms targeting the UK life sciences sector require market data to evaluate funding opportunities, assess portfolio company performance, and identify emerging players in the biologics safety testing space.
- Regulatory & Compliance Consultants : Consultancies advising biotech and pharma clients on UK regulatory matters need current market intelligence to provide informed guidance on safety testing requirements, timelines, and cost benchmarking.
Key Companies in the UK Biologics Safety Testing Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| PATHEON INC | Netherlands | Private Company | Drug Product Services (finished dosage manufacturing, packaging, lifecycle management),Pharmaceutical Development Services (formulation, clinical trial supply),Drug Substance Services (API and biologics substance), |
| SIGMA-ALDRICH CORPORATION | United States | Private Company | Chemicals and Biochemicals Catalog,Cell Culture, Media, and Critical Raw Materials,Filtration, Labware, and Water Purification, |
| WUXI PHARMATECH (CAYMAN) INC | China | Private Company | Chemistry drug CRDMO services,Biology discovery and preclinical testing,Clinical research services, |
| FLUOR CORPORATION | United States | Public Company | Energy Solutions (oil, gas, chemicals, LNG, power, energy transition),Urban Solutions (advanced technologies, life sciences, mining, infrastructure, staffing, maintenance),Mission Solutions (government, nuclear remediation, security, logistics, O&M), |
| AZELIS HOLDINGS SA | Belgium | Private Company | Coatings, Plastics & Advanced Materials Specialties,Food & Nutrition Ingredients,Personal Care & Home Care Ingredients, |
| CATALENT, INC. | United States | Private Company | Biologics (proteins, cell and gene, parenteral, large-molecule analytics),Pharma and Consumer Health – softgels and advanced oral dose (incl. Zydis),Pharma and Consumer Health – other oral, nasal, inhaled, topical, |
PATHEON INC
Patheon Inc. is a Netherlands-based private company with 9,100 employees operating in the pharmaceutical and biotechnology services sector.
SIGMA-ALDRICH CORPORATION
Sigma-Aldrich Corporation is a United States-based private company founded in 1951 with 9,800 employees specializing in life science and chemical products.
WUXI PHARMATECH (CAYMAN) INC
Wuxi Pharmatech (Cayman) Inc. is a China-based private company founded in 2000 with 8,837 employees providing pharmaceutical research and development services.
FLUOR CORPORATION
Fluor Corporation is a United States-based public company founded in 1912 with 22,995 employees operating in engineering, procurement, and construction services.
AZELIS HOLDINGS SA
Azelis Holdings SA is a Belgium-based private company founded in 2001 with 1,325 employees specializing in specialty chemicals and ingredients.
CATALENT, INC.
Catalent, Inc. is a United States-based private company founded in 1933 with 16,900 employees offering pharmaceutical development and manufacturing services.
Reasons to Buy this Report
- Regulatory Landscape Intelligence : Gain deep insights into MHRA and EMA regulatory requirements specific to the UK market, enabling companies to align their safety testing strategies with evolving compliance standards and avoid costly regulatory delays.
- Competitive Market Positioning : Understand the competitive dynamics among UK-based CROs, testing laboratories, and service providers. Identify market gaps and opportunities to differentiate your offerings in this high-growth segment.
- Investment & Growth Opportunities : Access detailed market sizing and forecasts to identify high-potential investment areas within the UK biologics safety testing sector, supporting strategic expansion and M&A decisions.
- Technology & Innovation Trends : Stay informed on emerging testing methodologies, alternative assay platforms, and digital solutions gaining traction in the UK market, enabling you to innovate ahead of competitors.
- Customer Demand Insights : Understand the specific needs and pain points of UK biopharmaceutical companies, biotech startups, and pharmaceutical manufacturers to tailor your products and services effectively.
Frequently asked questions
What is the current size of the UK biologics safety testing market?
The UK biologics safety testing market is valued at $339.6 million in 2026 and is projected to reach $584.9 million by 2031.
What is the expected growth rate for the UK market between 2026 and 2031?
The UK biologics safety testing market is expected to grow at a compound annual growth rate (CAGR) of 11.5% from 2026 to 2031.
What regulatory bodies oversee biologics safety testing in the UK?
The UK Medicines and Healthcare products Regulatory Agency (MHRA) and the European Medicines Agency (EMA) are the primary regulatory bodies overseeing biologics safety testing in the UK.
What testing methods are gaining adoption in the UK market?
The UK market is increasingly adopting in vitro testing methods and alternative technologies to reduce reliance on animal testing while maintaining safety standards.
Why is the UK an important market for biologics safety testing?
The UK is a leading life sciences hub in Europe with a strong pharmaceutical and biotechnology sector, numerous CROs, and stringent regulatory requirements that drive demand for comprehensive safety testing.
RESEARCH METHODOLOGY
This study involved four major activities in estimating the current size of the biologics safety testing market. Exhaustive secondary research was conducted to gather information on the market, its peer markets, and its parent market. These findings, assumptions, and sizing were then validated with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Following this, the data triangulation procedure was used to estimate the market size of segments and subsegments.
Secondary Research
Secondary research was primarily used to identify and gather information for the extensive, technical, market-oriented, and commercial study. The secondary sources referred for this research study include publications from government sources, such as the US Food and Drug Administration (FDA), World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), National Center for Biotechnology Information (NCBI), Organisation for Economic Co-operation and Development (OECD), National Institutes of Health (NIH), News Articles, Press Releases. Secondary sources also included corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. These sources were also used to obtain key information on major players, global product revenues, market classification, and segmentation by industry trends, regional/country-level markets, market developments, and technology perspectives. Secondary data were collected and analyzed to determine the overall size of the global biologics safety testing market, and the findings were validated through primary research.
Primary Research
In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among others, to obtain and verify critical qualitative and quantitative information and assess market prospects. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The global size of the biologics safety testing market was estimated through multiple approaches. A detailed market estimation approach was used to estimate and validate the market value and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
Data Triangulation
After estimating the overall market size from the market size estimation process, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, the data triangulation procedure was employed; it involved studying various factors and trends from both the demand and supply sides.
Market Definition
The biological safety testing market comprises the products and services used to assess the safety, purity, potency, and quality of biologically derived products across their development, manufacturing, and release stages.
Key Stakeholders
- Biologics safety testing products and services companies
- National and regional research boards and organizations
- Research & development companies
- Clinical research organizations (CROs)
- Biotechnology companies
- Research laboratories & academic institutes
- Market research & consulting firms
- Regulatory bodies
Report Objectives
- To define, describe, and forecast the biologics safety testing market by offering, test type, product application, service application, product end user, service end user, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall biologics safety testing market
- To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to six regions: North America (US and Canada), Europe (Germany, France, the UK, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), Latin America (Brazil, Mexico, Argentina, and the Rest of Latin America), the Middle East [GCC (Saudi Arabia (KSA), United Arab Emirates (UAE), and the Rest of GCC) and the Rest of Middle East], and Africa
- To profile the key players and analyze their market shares and core competencies
- To track and analyze competitive developments, such as product launches, partnerships, agreements, collaborations, and expansions
- To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy.
Available customizations:
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
Geographical Analysis
- Further breakdown of the Rest of Europe biologics safety testing market, by country
- Further breakdown of the Rest of Asia Pacific biologics safety testing market, by country
Company Information
- Detailed analysis and profiling of additional market players (up to five)
Segment Analysis
- Cross-segment analysis
Get the Full Biologics Safety Testing Market Report
Full forecast, segment splits, and company analysis for all Biologics Safety Testing Market.
- US Biologics Safety Testing Market
- Canada Biologics Safety Testing Market
- Germany Biologics Safety Testing Market
- France Biologics Safety Testing Market
- Italy Biologics Safety Testing Market
- Spain Biologics Safety Testing Market
- China Biologics Safety Testing Market
- Japan Biologics Safety Testing Market
- India Biologics Safety Testing Market
- South Korea Biologics Safety Testing Market
- Australia Biologics Safety Testing Market
- Brazil Biologics Safety Testing Market
- Mexico Biologics Safety Testing Market
- Saudi Arabia Biologics Safety Testing Market
- UAE Biologics Safety Testing Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report